Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology

Comment

Alan J Wein. J Urol. 2022 Jan.

. 2022 Jan;207(1):233-236.

doi: 10.1097/JU.0000000000002287. Epub 2021 Oct 18.

No abstract available

Comment on

Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Wakuda H, Shinozuka K. Yamada S, et al. J Pharmacol Exp Ther. 2021 May;377(2):201-206. doi: 10.1124/jpet.120.000301. Epub 2021 Mar 3. J Pharmacol Exp Ther. 2021. PMID: 33658313
Overactive bladder phenotypes: development and preliminary data.
Blaivas JG, Li ESW, Dayan L, Edeson ME, Mathew J, O'Boyle AL, Amare BL, Chaikin DC, Weiss JP, Kreder KJ. Blaivas JG, et al. Can J Urol. 2021 Jun;28(3):10699-10704. Can J Urol. 2021. PMID: 34129465
Re: The pathophysiology of stress urinary incontinence: a systematic review and meta-analysis. Int Urogynecol J 32, 501-552 (2021).
Petros PE. Petros PE. Int Urogynecol J. 2021 Oct;32(10):2881. doi: 10.1007/s00192-021-04900-0. Epub 2021 Jul 6. Int Urogynecol J. 2021. PMID: 34228154 No abstract available.
Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis/bladder pain syndrome with or without Hunner lesions.
Evans R, Kohan A, Moldwin R, Radecki D, Geib T, Peters KM. Evans R, et al. Neurourol Urodyn. 2021 Sep;40(7):1730-1739. doi: 10.1002/nau.24702. Epub 2021 Jul 20. Neurourol Urodyn. 2021. PMID: 34288094 Clinical Trial.